23-LEUK-24-BF-PMC(COVALENT-103): A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute Leukemia

Grants and Contracts Details

StatusActive
Effective start/end date1/31/24 → 1/31/26

Funding

  • Biomea Fusion Incorporated: $41,850.00